By discover and develop innovative biological MSC stem cells therapies and make them accessible to patients throughout the world.
By keeping our patients’ and customers’ safety and well-being at the core of everything we do.
By partnering with leading hospitals and healthcare professionals, and academia.
StemMedical® has spent years modifying and perfecting a commercially viable stem cell-enriched fat grafting solution for cosmetic treatments and now expanding into regenerative therapies and anti-inflammatory conditions.
Our founder, Dr. Stig-Frederik Trojahn Kølle, acknowledged the benefits of using a patient’s own fat for cosmetic treatments (e.g., breast augmentation, facial filling, wrinkle treatment and skin rejuvenation), as this material will always be biocompatible, natural appearing, non-immunogenic and versatile.
However, the transplanted fat graft is unpredictable and often has low survival. Thus, several procedures are needed to achieve an acceptable cosmetic outcome. Moreover, such transplants may not result in patient satisfaction and may not be a viable option for all people (e.g., thin people).
Inspired by scientific findings, StemMedical® was established in 2014 in Copenhagen, Denmark to begin modifying and perfecting a commercially viable stem cell-enriched fat grafting solution for various cosmetic treatments.
After targeted developmental work, we are now able to offer what we believe is a safe, natural, reliable, effective, and permanent fat grafting solution tailored to and around the individual patient. This treatment solution provides huge advantages over current artificial, synthetic, temporary, and unreliable cosmetic solutions.
We are proud to be pioneers of this new treatment regimen in modern plastic surgery and are committed to serving our patients and customers at the highest standards to always ensure satisfaction across the board while working hard to make the innovative treatments accessible to as many people as possible both geographically and economically.
Chief Executive Officer
Formally joined in August 2022 and comes from an 18-year tenure at Novo Nordisk, where he held various senior roles across the value chain and geographies.
He was globally responsible for the launches of Ozempic and Rybelsus. Most recently, he was Managing Director of Novo Nordisk’s stem cell division. Klaus also holds experience from strategy consulting.
Dr. Fred Koelle, MD, Ph.D
Chief Scientific Officer
MD, Ph.D., founded the company based on his extensive research and clinical experience.
Previously being the CEO, Fred has transitioned into the Chief Scientific Officer – with focus on R&D – but also acting as Brand Ambassador (via his active role as Board Certified plastic surgeon in leading clinics) and performing surgical training and KOL stewardship.
Marc Fauerby Lange
Chief Commercial Officer
Formally joined in January 2022 as Chief Commercial Officer to lead the commercial rollout, after being engaged as executive consultant since 2019.
Marc brings significant sales and marketing experience from business development as well as start-up experience from multiple entrepreneurial endeavours within various industries.
Chief Operating Officer
Co-founded the company with Fred Koelle. Peter is today in charge of Operations, covering manufacturing and supply chain.
Previous work experience includes 10 years of international management within projects, operations, trading, sales & marketing, and business development responsibilities in Shell (London & Nordics).
Chief Financial Officer
Joined formally as CFO in August 2022. He brings more than 20 years of experience from corporate, strategic, and financial management – of which many in life science companies such as Coloplast and Novozymes.
Additionally, he brings experience from investment banking and management consulting.
Anne Lykke Fisher Nielsen, MD PhD
Head of Quality & Regulatory
Anne is heading Quality and Regulatory. Anne is a board-certified clinical immunologist.
Anne has 20 years of experience in blood and cell therapy and has for a decade been Head of the Cell Therapy Facility at the Blood Bank at Rigshospitalet (Copenhagen University Hospital)
Board of directors
Stig Løkke Pedersen
Stig-Frederik Trojahn Kølle
Anders Christian Wolf Kølle
PhD, Research Fellow Harvard
Christina Molt Wengel
Master’s Degree Medical Science
Chia Chi Kao
Ass. Professor, Kao Plastic Surgery, California (US)
Ass. Professor, Akademikliniken, Artclinic, Stockholm (SE)
Head Surgeon, Aleris-Hamlet (DK)
Prof. Adam J Katz
Plastic Surgery at Wake Forrest School of Medicine, Founder GID Group, IFATS (US)
Former CEO, Novartis
Former CEO, Sandoz
BM, Xellia Pharma
Former Senior Executive, Novartis